Antimalarial Inhibitors that Target the Plasmodial Surface Anion Channel (PSAC) Protein and Development of the PSAC Protein as Vaccine Targets

There are two related technologies, the first being small molecule inhibitors of the malarial plasmodial surface anion channel (PSAC) and the second being the PSAC protein itself as a vaccine candidate. The PSAC protein is produced by the malaria parasite within host erythrocytes and is crucial for mediating nutrient uptake. In vitro data show that the PSAC inhibitors are able to inhibit growth of malaria parasites, have high specificity, and low toxicity. Portions of the PSAC protein are found on the outer surface of infected host erythrocytes and the protein was recently shown to be encoded by the clag3 gene. This discovery opens the possibility of developing the PSAC protein as a potential vaccine candidate against malaria.

Potential Commercial Applications: Competitive Advantages:
  • Antimalarial drugs
  • Malaria vaccine
  • Novel target against malaria
  • Small molecule inhibitors of PSAC inhibit malarial parasite growth, have low toxicity, and high specificity
  • PSAC protein is exposed on the surface of the infected host erythrocytes, making it an attractive vaccine candidate

Development Stage:
  • Early-stage
  • Pre-clinical
  • In vitro data available

Related Invention(s):


Sanjay Desai (NIAID)  ➽ more inventions...

Intellectual Property:
U.S. Pat: 9,808,458 issued 2017-11-07
U.S. Pat: 9,320,786 issued 2016-04-26
U.S. Pat: 10,265,313 issued 2019-04-23
U.S. Pat: 10,869,865 issued 2020-12-22
US Application No. 15/723,677
US Application No. 16/292,722
US Application No. 17/115,317

Pillai AD, et al. PMID 22949525
Desai SA. PMID 22432505
Nguitragool W, et al. PMID 21620134
Pillai AD, et al. PMID 20101003

Collaboration Opportunity:

The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Antimalarial Inhibitors that Target the Plasmodial Surface Anion Channel (PSAC) Protein. For collaboration opportunities, please contact Dana Hsu at or 301-451-3521.

Licensing Contact:
Peter Tung, Ph.D., M.B.A.
Phone: 240-669-5483

OTT Reference No: E-145-2011-0
Updated: Jan 5, 2021